Cencora (COR) Stock Buyback History
TTM buyback yield N/A.
COR
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
-4.7%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
-70.8%
5Y CAGR of spend
+0.7%
Peak year (2016)
$2.27B
Cumulative spend
$17.98B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Diluted share count is down 4.7% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- Cash buyback spend has compounded at +0.7% per year over the latest 5-year window.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $435.47M | $0.00 | $435.47M | 0.20B | -2.5% | 0.72% |
| 2024 | $1.49B | $148.00M | $1.34B | 0.20B | -2.1% | 3.34% |
| 2023 | $1.18B | $124.62M | $1.06B | 0.20B | -3.1% | 3.23% |
| 2022 | $483.70M | $93.40M | $390.30M | 0.21B | 1.3% | 1.73% |
| 2021 | $82.15M | $99.59M | −$17.44M | 0.21B | 1.8% | 0.33% |
| 2020 | $420.45M | $74.41M | $346.04M | 0.20B | -3.3% | 2.13% |
| 2019 | $674.03M | $58.87M | $615.16M | 0.21B | -3.9% | 3.94% |
| 2018 | $639.24M | $62.32M | $576.92M | 0.22B | -0.6% | 3.20% |
| 2017 | $329.93M | $62.21M | $267.72M | 0.22B | -1.9% | 1.82% |
| 2016 | $2.27B | $64.99M | $2.20B | 0.23B | 3.8% | 12.80% |
| 2015 | $2.04B | $60.94M | $1.98B | 0.22B | -7.5% | 10.12% |
| 2014 | $753.93M | $43.11M | $710.82M | 0.24B | 0.0% | 4.35% |
| 2013 | $484.18M | $36.27M | $447.90M | 0.24B | -8.4% | 3.44% |
| 2012 | $1.16B | $26.12M | $1.14B | 0.26B | -7.5% | 12.27% |
| 2011 | $840.58M | $28.36M | $812.21M | 0.28B | -3.3% | 8.47% |
| 2010 | $470.36M | $30.84M | $439.51M | 0.29B | -5.1% | 5.50% |
| 2009 | $450.35M | $27.14M | $423.21M | 0.30B | -6.8% | 6.88% |
| 2008 | $680.62M | $0.00 | $680.62M | 0.32B | -13.5% | 11.55% |
| 2007 | $1.44B | $0.00 | $1.44B | 0.38B | -9.4% | 18.34% |
| 2006 | $719.25M | $0.00 | $719.25M | 0.41B | -3.8% | 8.00% |
| 2005 | $787.76M | $0.00 | $787.76M | 0.43B | -8.5% | 9.58% |
| 2004 | $145.69M | $0.00 | $145.69M | 0.47B | 1.6% | 2.42% |
| 2003 | $0.00 | $0.00 | $0.00 | 0.46B | 3.3% | — |
| 2002 | $0.00 | $0.00 | $0.00 | 0.45B | 78.7% | — |
| 2001 | $0.00 | $0.00 | $0.00 | 0.25B | 20.7% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 0.21B | 0.7% | — |
| 1999 | $400.00K | $0.00 | $400.00K | 0.21B | 1.9% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.20B | 1.2% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.20B | 8.7% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.18B | — | — |
| 1995 | $5.70M | $0.00 | $5.70M | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Cencora (COR) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Cencora (COR)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Cencora (COR)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $435.47M | -70.8% | -$1.06B | ||
| 2024 | $1.49B | +26.3% | +$310.64M | ||
| 2023 | $1.18B | +144.1% | +$697.02M | ||
| 2022 | $483.70M | +488.8% | +$401.55M | ||
| 2021 | $82.15M | -80.5% | -$338.30M | ||
| 2020 | $420.45M | -37.6% | -$253.58M | ||
| 2019 | $674.03M | +5.4% | +$34.80M | ||
| 2018 | $639.24M | +93.7% | +$309.31M | ||
| 2017 | $329.93M | -85.4% | -$1.94B | ||
| 2016 | $2.27B | +11.1% | +$227.24M | ||
| 2015 | $2.04B | +170.5% | +$1.29B | ||
| 2014 | $753.93M | +55.7% | +$269.75M | ||
| 2013 | $484.18M | -58.3% | -$678.07M | ||
| 2012 | $1.16B | +38.3% | +$321.67M | ||
| 2011 | $840.58M | +78.7% | +$370.22M | ||
| 2010 | $470.36M | +4.4% | +$20.01M | ||
| 2009 | $450.35M | -33.8% | -$230.27M | ||
| 2008 | $680.62M | -52.6% | -$755.39M | ||
| 2007 | $1.44B | +99.7% | +$716.76M | ||
| 2006 | $719.25M | -8.7% | -$68.51M | ||
| 2005 | $787.76M | +440.7% | +$642.07M | ||
| 2004 | $145.69M | — | +$145.69M | ||
| 2003 | $0 | — | $0 | ||
| 2002 | $0 | — | $0 | ||
| 2001 | $0 | — | $0 | ||
| 2000 | $0 | -100.0% | -$400,000 | ||
| 1999 | $400,000 | — | +$400,000 | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | -100.0% | -$5.70M | ||
| 1995 | $5.70M | — | +$5.70M | ||
| 1994 | $0 | — | — |
Cencora (COR) most recent annual buyback spend stands at $435.47M (2025) – plunged 70.8% year-over-year.
Through 2020–2025 (5 years), Cencora buyback spend delivered a +0.7% annualised rate; with the latest reading among the more recent periods of the dataset.
Cencora buyback spend peaked at $2.27B in 2016; the latest annual figure is $435.47M in 2025 (80.8% below peak).
The dataset's maximum buyback spend sits at $2.27B (2016); the minimum reading of $0 dates to 1994.
Within Healthcare, Cencora (COR) ranks 8th among 8 peers we track. The peer median for buyback spend is $2.75B.
Cencora Buyback Spend 2025: $435.47M
Cencora buyback spend in 2025 was $435.47M, plunged 70.8% below 2024.
Cencora Buyback Spend 2024: $1.49B
Cencora buyback spend in 2024 was $1.49B, grew 26.3% from 2023.
Cencora Buyback Spend 2023: $1.18B
Cencora buyback spend in 2023 was $1.18B, surged 144.1% from 2022.
Cencora Buyback Spend 2022: $483.70M
Cencora buyback spend in 2022 was $483.70M, surged 488.8% from 2021.
Cencora Buyback Spend 2021: $82.15M
Cencora buyback spend in 2021 was $82.15M.
See more financial history for Cencora (COR).
Sector peers by buyback spend
Companies in the same sector as Cencora, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Cencora splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.10B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Cencora's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Cencora buy back its own stock?
Yes, Cencora (COR) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Cencora diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Cencora's share count changed?
Diluted weighted average shares changed by about -4.7% over roughly five fiscal years (annual income statement data).
What is Cencora's buyback spend?
Latest reported buyback spend for Cencora (COR) is $0 (period ending March 31, 2026).
How has Cencora buyback spend changed year-over-year?
Cencora (COR) buyback spend changed -70.8% year-over-year on the latest annual filing.
What is the long-term growth rate of Cencora buyback spend?
Cencora (COR) buyback spend compound annual growth rate is +0.7% over the most recent 5 years available.
When did Cencora buyback spend hit its highest annual value?
Cencora buyback spend reached its highest annual value of $2.27B in 2016.
What was Cencora buyback spend in 2024?
Cencora (COR) buyback spend in 2024 was $1.49B.
What was Cencora buyback spend in 2025?
Cencora (COR) buyback spend in 2025 was $435.47M.
Explore more
COR Overview
Company profile, financial tools, and key metrics
COR Revenue Counter
Earns $10,422 every second. See per minute, hour, and day.
COR Earnings Counter
Earns $80.82 per second net profit. See per minute, hour, and day.
COR Economic Scale
Exceeds Portugal's GDP. Compare with world economies.
COR What If Invested
What if you had invested $1,000? See historical returns from any date.
COR How It Makes Money
Discover visual breakdown of $328.68B in revenue — where it comes from and where it goes.
COR Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
COR Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
COR Daily Price Character
Steady · 51.0% historical win rate (green days). Streaks & record days.
COR Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
COR Dividend Profile
Yield: 0.89%. Safety: 6/8. See full history.
COR Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
COR Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
COR Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
COR Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.